• Lumiracoxib Workflows for COX-2 Research

  2026-08-31

  Build cleaner COX-2 pathway experiments with Lumiracoxib, from biochemical inhibition assays to time-resolved inflammation and revascularization models. Its high COX-1 selectivity helps separate prostaglandin synthesis inhibition from broader cyclooxygenase effects, while a staged workflow exposes when COX-2 activity is protective or maladaptive.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-08-31

  HotStart™ 2X Green qPCR Master Mix is intended for SYBR Green real-time PCR of cDNA or DNA when nonspecific amplification and primer-dimer formation could compromise quantification. It is suitable for gene expression analysis, RNA-seq validation, and nucleic acid quantification after assay validation, but it should not be used as a direct RNA amplification reagent or treated as a probe-specific chemistry without separate validation.

• Phosbind Acrylamide: 5 Lab Scenarios

  2026-08-30

  This scenario-based guide explains how Phos binding reagent (Phosbind) acrylamide, SKU F4002, can support antibody-free SDS-PAGE phosphorylation analysis alongside cell viability, proliferation, and cytotoxicity studies. It covers compatibility, gel preparation, storage, mobility-shift interpretation, and practical vendor selection using product specifications and published phosphorylation research.

• Ferrostatin-1 (Fer-1) in Ferroptosis Assays

  2026-08-29

  Ferrostatin-1 (Fer-1) provides a practical rescue control for distinguishing lipid peroxidation–driven death from nonspecific cytotoxicity. This workflow applies Fer-1 to colorectal cancer studies, HDAC3–NRF2–GPX4 pathway analysis, and carefully bounded extensions into neuronal models.

• BCL-XL inhibitor A-1155463: Applied Research Workflow

  2026-08-28

  Build sharper apoptosis studies with a high-affinity, selective BCL-XL inhibitor that helps distinguish BCL-XL dependence from nonspecific cytotoxicity. This workflow covers model selection, dose-response design, mechanistic validation, resistance studies, and translational interpretation.

• HotStart™ 2X Green qPCR Master Mix for dAGE Studies

  2026-08-28

  Discover how HotStart™ 2X Green qPCR Master Mix can translate dAGE–myriocin biology into a defensible gene-expression assay strategy. This article connects SYBR Green chemistry, mechanism-resolving marker selection, and interpretation limits for metabolic research.

• Forsythoside E for PKM2 Macrophage Assays

  2026-08-27

  Forsythoside E connects PKM2 tetramerization with macrophage metabolic remodeling, making it useful for mechanism-driven inflammation and sepsis-induced liver injury research. This workflow pairs glycolysis, signaling, polarization, and target-engagement readouts instead of relying on cytokine measurements alone.

• FH1 and the Next Control Layer in Liver Research

  2026-08-27

  FH1 links iPS-derived hepatocyte maturation with a broader translational strategy: build more functional liver cell models first, then evaluate regulated gene expression in a biologically relevant context. This perspective connects FH1 (Catalog No. B3700) with the light-inducible RNA-releasing protein platform described in Trends in Biotechnology while clearly separating established findings from forward-looking research opportunities.

• IGFBP2–THBS1 Axis in GH-Mediated Bone Growth

  2026-08-26

  A 2025 study identifies an IGFBP2–THBS1 regulatory axis that helps explain how growth hormone promotes chondrocyte proliferation and hypertrophic differentiation in idiopathic short stature. Its combination of ISS-associated plasma proteomics, interaction prediction, and functional gene perturbation links GH exposure to IGF-1 pathway activity and suggests a mechanistic framework for studying variable treatment responses.

• EdU Flow Cytometry Assay Kits (Cy3) Guide

  2026-08-26

  EdU Flow Cytometry Assay Kits (Cy3) provide denaturation-free S-phase detection for RA-FLS, macrophage, cancer, and toxicology workflows. This guide connects click-chemistry DNA synthesis labeling with practical controls, multiplex design, and troubleshooting for more interpretable proliferation data.

• Liraglutide and the Brain–Kidney AVP Axis

  2026-08-25

  Greenwood and colleagues show that liraglutide lowers circulating arginine vasopressin in healthy humans and produces time- and sex-dependent synaptic phosphoproteomic changes in the rat pituitary. By combining clinical sampling, molecular profiling, an AVP luciferase assay, and renal signaling analysis, the study links GLP-1 receptor agonism to coordinated regulation of hormone release and aquaporin 2.

• Cefazedone PK/PD in Community-Acquired Pneumonia

  2026-08-25

  The reference study connected cefazedone plasma exposure, pathogen MIC values, and clinical response in patients with mild to moderate community-acquired pneumonia. Its main practical contribution was showing that 2 g every 12 hours produced a mean free-drug time above MIC of approximately 55%, supporting the studied intravenous regimen for infections caused by susceptible organisms.

• H89 Reverses ABCB1-Mediated Colorectal Cancer Resistance

  2026-08-24

  Liu and colleagues identify H89 as a potential multidrug-resistance modulator that restores sensitivity to ABCB1 substrate drugs in an HCT-8/V colorectal cancer model. Their data connect resistance reversal to impaired ABCB1 ATPase and efflux activity rather than reduced transporter expression, providing a mechanistic framework for testing combination strategies in cancer chemotherapy.

• Catalpol and the Sirt6–ERα–FasL Osteoporosis Axis

  2026-08-24

  This study identifies a mechanistic pathway by which catalpol protects ovariectomized rats from estrogen deficiency-induced osteoporosis: Sirt6-mediated ERα deacetylation increases FasL-dependent osteoclast apoptosis. Its combination of bone imaging, cellular assays, gene silencing, and co-immunoprecipitation provides a useful framework for distinguishing reduced osteoclast formation from active osteoclast elimination.

• GW 6471: PPARα Antagonist for Metabolic Research

  2026-08-23

  GW 6471 is a small molecule PPARα antagonist for mechanistic studies of receptor-dependent transcription. Its defined co-repressor mechanism supports cellular metabolism research, lipid homeostasis studies, and carefully bounded environmental toxicology experiments.

8388 records 1/560 page Next 12345 下5页 Last page